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Abstract
Objective. Study of the uptake of new medical technologies provides useful information on the transfer of published evidence
into usual practice. We conducted an audit of selected hospitals in three countries (Canada, France, and Switzerland) to identify
clinical predictors of low-molecular-weight (LMW) heparin use and outpatient treatment, and to compare the pace of uptake
of these new therapeutic approaches across hospitals.
Design. Historical review of medical records.
Setting and participants. We reviewed the medical records of 3043 patients diagnosed with deep vein thrombosis (DVT) in
five Canadian, two French, and two Swiss teaching hospitals from 1994 to 1998.
Measures. We explored independent clinical variables associated with LMW heparin use and outpatient treatment, and determined
crude and adjusted rates of LMW heparin use and outpatient treatment across hospitals.
Results. For the years studied, the overall rates of LMW heparin use and outpatient treatment in the study sample were 34.1 and
15.8%, respectively, with higher rates of use in later years. Many comorbidities were negatively associated with outpatient treatment,
and risk-adjusted rates of use of these new approaches varied significantly across hospitals.
Conclusion. There has been a relatively rapid uptake of LMW heparins and outpatient treatment for DVT in their early years
of availability, but the pace of uptake has varied considerably across hospitals and countries.
Keywords: anticoagulation, deep vein thrombosis, low-molecular-weight heparins, practice variation, process of care
Treatment of acute deep vein thrombosis (DVT) has under-
gone major change during the last decade. While initial in-
hospital treatment with intravenous unfractionated heparin
used to be the traditional treatment, there is strong published
evidence that subcutaneous low-molecular-weight (LMW)
heparins in one or two daily doses are at least as safe, effect-
ive, and more cost-effective than intravenous unfractionated
heparin [1,2]. Further, between 12 and 53% of patients with
DVT can be safely and effectively treated at home with sub-
cutaneous LMW heparins [3–5]. Outpatient treatment for
DVT has been shown to be highly cost-effective and likely to
be preferred by patients in comparison to in-hospital intraven-
ous heparin therapy [5,6].
New evidence is often adopted into practice with a signi-
ficant delay [7] and may show considerable geographic vari-
ation. This variation in practice across countries, hospitals, or
health care providers is a common finding that has been a fre-
quent focus for health care researchers interested in studying
quality of care [8,9]. The interest in studying practice variation
arises from the justifiable concern that variable processes of
care are an indicator of variable quality across providers.
Similarly, low rates of use of established therapies suggest
suboptimal care [10,11]. Such findings are valuable because
they provide information on where educational and quality
interventions are most needed and likely to improve care.
Given the new available approaches to DVT care and the
lack of studies documenting usual care practices for DVT
treatment, we conducted a multicenter study to: (i) identify
clinical predictors of LMW heparin use and outpatient treat-
ment in the management of DVT; (ii) compare use of these
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new treatment approaches across years; and (iii) use the
resulting information on clinical predictors to derive risk-
adjusted rates of LMW heparin use and outpatient treatment
in nine hospitals located in three countries.
Methods
Identification of cases
Based on established collaborative ties between investigators,
this multicenter study was conducted in nine teaching hos-
pitals, of which five are situated in Alberta, Canada, two in
France, and two in Switzerland. DVT cases from 1994 to
1998 were identified from emergency room records by
screening for emergency room contacts with any of the
following ICD-9-CM diagnosis codes: 451.11, 451.19, 451.2,
451.81, 451.83, 451.84, 451.89, 451.9, 453.2, 453.8, 453.9,
671.3x, 671.4x, or 671.9x. For each hospital, a random sample
of 75 DVT case records was selected from each of the years
1994 through 1998. For some hospitals, all cases of DVT
were reviewed because <75 cases were available. A total of
3226 patient records were reviewed in the nine hospitals.
Chart review
This sampling approach led to the identification of 3226
DVT cases. A careful review of the emergency room records
for these cases (and ensuing in-patient charts if patients were
admitted) was conducted to determine: (i) specific diagnosis
and whether or not there was a concomitant diagnosis or sus-
picion of pulmonary embolism, or a history of prior venous
thromboembolism; (ii) patient sociodemographic variables (age,
sex, year of admission); (iii) existence of any of the 17 co-
morbidity variables that constitute the Charlson index [12];
(iv) alcohol or street drug abuse; (v) indicators of instability
(i.e. any subjective indication in the chart that the patient
appears ‘unstable’, or explicit documentation of hypotension
or hypoxemia); (vi) history of bleeding (prior/current gastro-
intestinal bleeding) or condition associated with bleeding
risk (cerebral aneurysm/arteriovenous malformation, current
oral anticoagulation, history of stroke); and (vii) pregnancy. All
of these variables were collected because they were considered
a priori to be potential determinants of LMW heparin use
and/or outpatient therapy.
As a measure of overall LMW heparin use in the treatment
of DVT, we recorded for each patient whether or not a LMW
heparin was used at any given time in the management of the
patient (i.e. either initially, during hospitalization, or at dis-
charge). We also documented whether patients with DVT were
treated as outpatients or admitted for in-patient treatment.
Data analysis
We performed univariate comparisons between patients who
received LMW heparins as in-patients and those who were
treated in an outpatient setting. We compared continuous
variables using a two-sample Wilcoxon rank-sum test, and
categorical variables by using Fisher’s exact test. Two-sided
P values <0.05 were considered statistically significant.
In order to identify those clinical variables that are
independently associated with the use of LMW heparins, we
constructed logistic regression models with LMW heparin use
as the dependent variable. This analysis was repeated to
explore independent clinical predictors of outpatient treat-
ment. We avoided variable selection criteria based on uni-
variate statistical significance because our objective in these
analyses was simply to explore multivariable associations with
LMW heparin use and outpatient treatment.
From the logistic regression model, we calculated the
expected rate (E) of LMW heparin use for each of the nine
study hospitals. The observed rate of LMW heparin use (O)
was then divided by E to generate an O/E ratio for each
hospital by averaging individual patients’ model-predicted
probability of use within hospitals. To calculate the adjusted
rate of LMW heparin use for each hospital, we multiplied the
O/E ratio by the overall rate of use. This analysis was
repeated to calculate the expected rate, O/E ratio, and
adjusted rate for outpatient treatment. All analyses were
performed using STATA version 7.0 (Stata Corporation,
College Station, TX).
Results
Patient characteristics
We excluded 183 of the 3226 initially screened patients for
the following reasons: (i) no leg DVT on closer review of the
hospital records; (ii) admission before 1994 or after 1998; and
(iii) missing information about the method of treatment. As a
result, 3043 patients with objectively confirmed DVT were
included in our study analyses. Table 1 describes the charac-
teristics and comorbidities of the 3043 patients. The mean
age was 61.4 years and 49.7% of the study population were
women. Arterial hypertension (25.1%), any malignancy
(20%), and chronic lung disease (10%) were the most fre-
quent comorbidities. Twenty-nine percent of the study
patients had a previous history of venous thromboembolism.
In 22.8% of all cases, a concomitant pulmonary embolism
was either clinically suspected or objectively confirmed.
Nearly 8% of patients were considered ‘unstable’ or had
hypoxemia, but the prevalence of hypotension was low (1%).
Predictors of LMW heparin use
For 25.7% of all patients in our study sample, a LMW heparin
was the first anticoagulant used, while 1038 (34.1%) patients
were treated using it at some time. Of these, 62.6% received
traditional in-patient care whereas 37.4% were treated as out-
patients. In-patients who received LMW heparins were older
(64 versus 56 years; P < 0.001) and had significantly more
comorbid diseases than those who were treated with LMW
heparin as outpatients. Specifically, patients who received
LMW heparin as in-patients were more likely to have peri-
pheral vascular disease, arterial hypertension, malignancy,
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rheumatological diseases, suspected or confirmed pulmonary
embolism, and hypoxemia, and were more often considered
unstable than patients treated with LMW heparins as outpa-
tients (P < 0.001 for each pairwise comparison).
Multivariate associations between the use of LMW hep-
arins and the patient characteristics are shown in Table 2.
The strongest independent positive association with LMW
heparin use was the year of hospitalization. The odds ratios
(ORs) for patients being treated with LMW heparins rose
steadily from 1.00 in 1994 (the reference year) to 11.36 [95%
confidence interval (CI) 8.33–15.49] in 1998, reflecting the
rapid shift over time toward the use of LMW heparins in the
treatment of DVT. The evolution in use of LMW heparins
over time is also shown for all hospitals combined (Figure 1)
and by hospital (Figure 2).
Other variables independently associated with LMW
heparin use include the presence of rheumatological disease
(OR 2.04; 95% CI 1.44–2.90), human immunodeficiency virus
(OR 3.01; 95% CI 1.13–8.03), any malignancy (OR 1.33; 95%
CI 1.02–1.74), and an ‘unstable’ medical condition (OR 1.66;
95% CI 1.18–2.33). Significant negative associations with
LMW heparin use were generally more frequent than posi-
tive ones. Current oral anticoagulation (OR 0.74; 95% CI
0.55–0.98), cerebrovascular disease (OR 0.62; 95% CI 0.38–
0.99), chronic lung disease (OR 0.69; 95% CI 0.51–0.94),
peptic ulcer disease (OR 0.48; 95% CI 0.31–0.76), diabetes
with complications (OR 0.31; 95% CI 0.11–0.88), metastatic
solid tumor (OR 0.43; 95% CI 0.30–0.63), street drug abuse
(OR 0.34; 95% CI 0.12–0.99), and hypoxemia (OR 0.44; 95%
CI 0.30–0.66) were all independently associated with less
LMW heparin use.
Predictors of outpatient treatment
Outpatient treatment was used for 15.8% of patients. Multi-
variate associations between outpatient treatment and the
patient characteristics are shown in Table 2. The only signi-
ficant positive independent association with outpatient
treatment was the year of hospitalization, with ORs rising
steadily from 1.00 in 1994 to 11.67 (95% CI 7.49–18.17) in
1998. The evolution in use of outpatient treatment over
time is also shown for all hospitals (Figure 1) and by hospital
(Figure 3).
Independent patient factors negatively associated with out-
patient treatment were current oral anticoagulation (OR 0.54;
95% CI 0.33–0.87), unstable or stable angina (OR 0.17; 95%
CI 0.07–0.44), arterial hypertension (OR 0.60; 95% CI 0.44 –
0.82), peptic ulcer disease (OR 0.33; 95% CI 0.15–0.75),
metastatic solid tumor (OR 0.46; 95% CI 0.24–0.87), rheumato-
logical disease (OR 0.43; 95% CI 0.21–0.86), suspected or
confirmed pulmonary embolism (OR 0.08; 95% CI 0.04–0.14),
‘unstable’ medical condition (OR 0.23; 95% CI 0.09–0.59),
hypoxemia (OR 0.08; 95% CI 0.01–0.55), and pregnancy (OR
0.16; 95% CI 0.04–0.74). The last four negative associations
were particularly strong. Older age nearly achieved statistical
significance (OR 0.94 for 10-year increments; 95% CI 0.88–1.00;
P = 0.05). The patient characteristics moderate/severe liver
disease, diabetes with complications and street drug abuse could
not be included in the multivariate analysis for predictors of
outpatient treatment, as none of these patients were treated as
outpatients.
Inter-hospital comparison
Table 3 shows the crude and adjusted rates of LMW heparin
use and outpatient treatment (i.e. proportions of DVT
patients treated with LMW heparins and as outpatients) in the
Table 1 Characteristics of 3043 patients with deep vein
thrombosis in nine hospitals between 1994 and 1998
SD = standard deviation.
1Designates subjective measures of instability (e.g. ‘looks unwell’,
‘diaphoretic’) rather than traditional vital parameters.
2Systolic blood pressure <90 mmHg.
3paO2 <60 mmHg or O2 saturation <90%.
Mean age ± SD (years) 61.4 ± 18.6
Females, n (%) 1513 (49.7)
Prior history of venous 
thromboembolism, n (%)
880 (28.9)
Prior history of stroke, n (%) 127 (4.2)
Prior/current gastrointestinal 
bleeding, n (%)
107 (3.5)
Brain aneurysm/arteriovenous 
malformation, n (%)
23 (0.8)
Current oral anticoagulation, n (%) 334 (11)
Peripheral vascular disease, n (%) 147 (4.8)
Unstable or stable angina, n (%) 226 (7.4)
Myocardial infarction, n (%) 124 (4.1)
Congestive heart failure, n (%) 213 (7)
Cerebrovascular disease, n (%) 159 (5.2)
Arterial hypertension, n (%) 763 (25.1)
Chronic lung disease, n (%) 304 (10)
Peptic ulcer disease, n (%) 156 (5.1)
Mild liver disease, n (%) 50 (1.6)
Moderate/severe liver disease, n (%) 23 (0.8)
Chronic renal disease, n (%) 109 (3.6)
Diabetes mellitus, n (%) 219 (7.2)
Diabetes with complications, n (%) 28 (0.9)
Any malignancy, n (%) 608 (20)
Metastatic solid tumor, n (%) 300 (9.9)
Human immunodeficiency virus 
disease, n (%)
21 (0.7)
Rheumatological disease, n (%) 172 (5.7)
Dementia, n (%) 137 (4.5)
Hemi-/paraplegia, n (%) 112 (3.7)
Alcohol abuse, n (%) 198 (6.5)
Street drug abuse, n (%) 27 (0.9)
Suspected or confirmed pulmonary 
embolism, n (%)
695 (22.8)
‘Unstable-looking patient’1, n (%) 227 (7.5)
Arterial hypotension2, n (%) 29 (1)
Hypoxemia3, n (%) 232 (7.6)
Pregnancy, n (%) 24 (0.8)
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nine study hospitals. Expected rates of LMW heparin use and
outpatient treatment are also shown. The observed rate of
LMW heparin use and outpatient treatment varied markedly
from 9.0 to 80.5% and 0 to 46.4%, respectively. The expected
rate of LMW heparin use and outpatient treatment calculated
from the multivariate models shown in Table 3 also varied
somewhat, from 27.1 to 41.5% and 6.0 to 24.1%, respectively.
These differences in model-predicted rates of use reflect the
Table 2 Clinical characteristics associated with low-molecular-weight (LMW) heparin use and out-
patient treatment
CI, confidence interval; VTE, venous thromboembolism; GI, gastrointestinal; AV, arteriovenous; AIDS,
acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; PE, pulmonary embolism.
1Logistic regression model with LMW heparin as a dependent variable and the clinical characteristics listed in
this table as independent variables had an area under the receiver operating characteristic (ROC) curve of 0.74.
2Logistic regression model with outpatient treatment as a dependent variable and the clinical characteristics
listed in this table as independent variables had an area under the ROC curve of 0.84.
Characteristic
...........................................................................................
Multivariate odds ratio (95% CI)
LMW heparin use1 Outpatient treatment2
.............................................................................................................................................................................
Age (10-year increments) 0.99 (0.94–1.04) 0.94 (0.88–1.00)
Female sex 1.16 (0.98–1.38) 1.10 (0.87–1.37)
Year of hospitalization
1994 1.00 (reference) 1.00 (reference)
1995 2.17 (1.57–3.00) 1.24 (0.73–2.11)
1996 3.77 (2.76–5.15) 4.03 (2.54–6.40)
1997 6.51 (4.81–8.83) 6.74 (4.31–10.52)
1998 11.36 (8.33–15.49) 11.67 (7.49–18.17)
Prior history of VTE 1.04 (0.86–1.26) 0.81 (0.62–1.05)
Prior history of stroke 1.33 (0.80–2.23) 0.34 (0.11–1.01)
Prior history of GI bleeding 0.89 (0.54–1.46) 0.52 (0.22–1.22)
Brain aneurysm/AV malformation 0.61 (0.23–1.60) 0.20 (0.02–1.62)
Current oral anticoagulation 0.74 (0.55–0.98) 0.54 (0.33–0.87)
Peripheral vascular disease 1.43 (0.97–2.13) 0.79 (0.39–1.64)
Unstable or stable angina 0.97 (0.69–1.36) 0.17 (0.07–0.44)
Myocardial infarction 1.13 (0.73–1.74) 1.22 (0.64–2.35)
Congestive heart failure 0.97 (0.68–1.38) 1.08 (0.61–1.93)
Cerebrovascular disease 0.62 (0.38–0.99) 1.16 (0.51–2.61)
Arterial hypertension 0.98 (0.80–1.20) 0.60 (0.44–0.82)
Chronic lung disease 0.69 (0.51–0.94) 0.81 (0.52–1.25)
Peptic ulcer disease 0.48 (0.31–0.76) 0.33 (0.15–0.75)
Mild liver disease 1.07 (0.55–2.09) 1.30 (0.47–3.57)
Moderate/severe liver disease 2.14 (0.81–5.65) NA
Chronic renal disease 0.84 (0.53–1.35) 0.92 (0.45–1.91)
Diabetes mellitus 0.90 (0.65–1.24) 0.76 (0.46–1.25)
Diabetes with complications 0.31 (0.11–0.88) NA
Any malignancy 1.33 (1.02–1.74) 0.74 (0.50–1.09)
Metastatic solid tumor 0.43 (0.30–0.63) 0.46 (0.24–0.87)
AIDS/HIV disease 3.01 (1.13–8.03) 0.70 (0.14–3.56)
Rheumatological disease 2.04 (1.44– 2.90) 0.43 (0.21–0.86)
Dementia 1.42 (0.96–2.11) 0.43 (0.21–0.86)
Hemi-/paraplegia 1.03 (0.64–1.66) 0.41 (0.17–1.02)
Alcohol abuse 0.91 (0.63–1.32) 0.63 (0.36–1.11)
Street drug abuse 0.34 (0.12–0.99) NA
Suspected/confirmed PE 0.83 (0.67–1.02) 0.08 (0.04–0.14)
‘Unstable looking patient’ 1.66 (1.18–2.33) 0.23 (0.09–0.59)
Arterial hypotension 0.42 (0.16–1.16) 0.25 (0.03–2.20)
Hypoxemia 0.44 (0.30–0.66) 0.08 (0.01–0.55)
Pregnancy 0.61 (0.24–1.58) 0.16 (0.04–0.74)
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differing average severity of illness across hospitals. The ratios
of O/E treatment use are also shown in Table 3. Values >1.0
indicate greater-than-average use, while values <1.0 indicate
lower than average use. The O/E ratios are then used to cal-
culate the risk-adjusted rates of LMW heparin use and outpa-
tient therapy use, shown in Table 3 (adjusted rate = O/E ×
average rate). The differences between the observed and
adjusted rates were generally quite small, although adjustment
did occasionally change rates notably.
Between-country comparisons
While we fully recognize that the selected hospitals are not
necessarily representative of the countries in which they
reside, we nevertheless compared treatment strategies across
the three countries. The adjusted rates of LMW heparin use
were 26.2% for Canada, 63.0% for France, and 25.0% for
Switzerland. For outpatient treatment, the adjusted rates were
17.2% for Canada, 1.8% for France, and 20.3% for Switzerland.
Discussion
Our results show that a number of clinical variables were
positively and negatively associated with LMW heparin use
and outpatient treatment. As most outpatients are treated
with LMW heparins, many of the observed associations are
common to both analysis endpoints. The strongest positive
predictor for both LMW heparin use and outpatient treat-
ment turned out to be the year of hospitalization, with later
years being associated with greater use of the new treatment
methods. The steady rise in the uptake of LMW heparins and
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Figure 1 Overall low-molecular-weight heparin use and outpatient treatment for all nine hospitals. LMWH, low-molecular-
weight heparin.
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Figure 2 Low-molecular-weight heparin use in the nine hospitals studied, by hospital.
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outpatient treatment over time reflects a relatively rapid
response to new evidence as compared, for example, with the
historical example of sluggish uptake of thrombolysis for
acute myocardial infarction [7]. Based on these data, it is
conceivable that some of the hospitals studied will have
succeeded in treating almost all eligible patients with these
new treatments by 2004. The proportion of patients who are
eligible for outpatient treatment will vary somewhat across
hospitals, but may be 75–80%, or even higher.
There were a number of patient factors negatively asso-
ciated with outpatient treatment that seem to reflect highly
appropriate clinical decisions. Indeed, patients with multiple
comorbidities and complex medical issues may not be ideal
candidates for outpatient treatment with LMW heparins. We
also found that variables indicative of bleeding risk (oral anti-
coagulation, peptic ulcer disease) were associated with lower
use of LMW heparins, perhaps reflecting a reluctance among
providers—which may or may not be appropriate—to use
LMW heparins in the face of bleeding risk. Interestingly,
although LMW heparin use is negatively associated with
pulmonary embolism, this association is not significant. A pos-
sible explanation is that ∼30% of patients with concomitant
proven or suspected pulmonary embolism were treated with
LMW heparins. Furthermore, there is growing evidence in the
medical literature that this approach is safe and effective, at
least in patients with submassive pulmonary embolism 13–15.
While LMW heparin use is positively associated with the pres-
ence of any malignancy, its use has a negative association with
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Figure 3 Outpatient treatment in the nine hospitals studied, by hospital.
Table 3 Observed and adjusted rates of low-molecular-weight (LMW) heparin use and outpatient treatment according to
hospital site between 1994 and 1998
1The ratio between the observed and expected rate of LMW heparin use.
2Rate is adjusted for all of the clinical variables listed in Table 2.
3The ratio between the observed and expected rate of outpatient treatment.
Hospital Number 
of cases .........................................................................................
LMW heparin use
...................................................................................
Outpatient treatment
Expected 
rate (%)
Observed 
rate (%)
O/E 
ratio1
Adjusted 
rate2 (%)
Expected 
rate (%)
Observed 
rate (%)
O/E 
ratio3
Adjusted 
rate2 (%)
.........................................................................................................................................................................................................................
1 347 34.0 13.5 0.40 13.5 17.6 13.8 0.78 12.4
2 376 27.1 17.0 0.63 21.4 9.0 7.5 0.84 13.2
3 375 34.0 31.2 0.92 31.3 17.5 21.6 1.24 19.6
4 335 33.1 57.6 1.74 59.3 6.0 2.1 0.35 5.6
5 340 32.7 27.1 0.83 28.3 14.4 22.9 1.59 25.2
6 319 33.1 26.3 0.79 27.1 19.7 22.6 1.15 18.1
7 287 41.5 80.5 1.94 66.1 14.7 0.0 0 0.0
8 308 39.3 57.8 1.47 50.2 24.1 46.4 1.92 30.4
9 356 34.6 9.0 0.26 8.9 20.6 6.7 0.32 5.1
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metastatic solid tumor. A possible explanation for this discrep-
ancy could be that many patients with metastasis (some of
them with brain metastasis) present an elevated bleeding risk
or are so ill that anticoagulation with LMW heparins is per-
ceived by treating physicians not to be a desirable option.
The results of the inter-hospital comparison show that
observed rates of LMW heparin use and outpatient treatment
are highly variable, even after adjustment for all of the patient
factors listed in Table 1. Such adjustment creates a ‘level play-
ing field’ for inter-hospital and between-country compari-
sons. With adjustment, LMW heparin use across hospitals
varied from 8.9 to 66.1%, and outpatient treatment varied
from 0 to 30.4%. Somewhat surprisingly, however, the two
hospitals (4 and 7) with the highest rates of LMW heparin use
had the lowest rates of outpatient treatment. These findings
add to the results of a previous study which found consider-
able variation in the prophylactic use of LMW heparins
among British hospitals [16].
Similar to the inter-hospital comparison, the between-
country comparison of patient-factor-adjusted LMW heparin
use and outpatient treatment exhibited large variability. The
adjusted rates of LMW heparin use varied between 26.2 and
62.9%, while those for outpatient treatment ranged from 1.8
to 20.3% of the study patients. As there are only few clinical
situations where unfractionated heparin may be superior to
LMW heparins (e.g. renal insufficiency), these findings
suggest that LMW heparin therapy was generally underused
in our study population. Although the rates of outpatient
treatment in our study are consistent with the variability in
rates of use reported in the literature (12–53% [4–6]), four
out of nine hospitals had observed outpatient treatment rates
of <10%, clearly indicating under-use. An important caveat to
this interpretation, however, is that we only studied the early
years of availability of LMW heparins.
There are several possible reasons for the marked variation
between hospitals and countries in the extent to which LMW
heparins and outpatient treatment are used. There may exist
differences across hospitals and/or countries in the timing of
licensing of new medications, formulary changes (at hospital
level), health insurance coverage, local bed pressures, and
varying degrees of physician comfort with new drugs. In addi-
tion, the development of infrastructure necessary to support
outpatient care may vary across regions and countries. We
cannot rule out the possibility that the small percentage of
patients treated as outpatients in some centres could relate to
unique local practice patterns that channel outpatient DVT
patients toward outpatient treatment centres, bypassing
hospitals entirely (case sampling for this study was hospital-
based).
Notable strengths of this study are the collection of detailed
clinical data on usual care practices for DVT, and the compila-
tion of data on >3000 patients treated in nine hospitals and
three countries. Further, the collection of data from a 5-year
time period provides a longitudinal perspective on the uptake
of new therapeutic approaches to DVT. This study is thus use-
ful in documenting the early years of the transition from purely
in-patient therapy for DVT with unfractionated heparin to
increasing use of LMW heparins and outpatient therapy.
An acknowledged limitation of our study is the non-
random selection of hospital centers in three countries. How-
ever, we anticipate that similar variation would also probably
have been seen with a random hospital sample. Further, as
the review of >3000 charts in nine hospitals has been a time-
consuming task, our study documents only the early years
(1994–1998) of the practice change. A review of more recent
years in future work, for which this study provides baseline
information, may reveal a further increase in the uptake of
LMW heparins and outpatient treatment.
Finally, our study focused on clinical factors as predictors
of utilization of LMW heparins and outpatient treatment.
There are also notably a number of physician and system
structure factors that could influence the utilization of LMW
heparins and outpatient treatment in patients with DVT [17].
Examples of such factors include the presence or absence of
hospital guidelines for DVT care, the timing of the addition
of LMW heparins to hospital formularies, and the availability
of outpatient clinics for close follow-up of outpatients. A stat-
istically meaningful exploration of such factors would have
necessitated the systematic collection of structural data, and
the inclusion of a much larger number of study sites, an
undertaking that was clearly beyond the scope of this project.
These limitations notwithstanding, our study is useful in
documenting a steady and relatively rapid uptake of LMW
heparins and outpatient treatment in nine hospitals. A number
of clinical variables appear to be appropriately guiding clinical
decisions around these new therapies. The marked variation
in practice between hospitals and countries indicates, how-
ever, that providers in some hospitals have been more sluggish
than others in their adoption of a new standard for the treat-
ment of DVT. Educational and quality interventions may be
needed in some centers to accelerate the uptake of novel and
efficacious approaches to managing DVT. Further research
should focus on potential associations between structural fac-
tors and processes of care in the management of DVT.
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